Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus

World Journal of Gastroenterology

Volumn 19, Issue 48, 2013, Pages 9282-9293

  Noble, Fergus ^a,b   Nolan, Luke ^a   Bateman, Adrian C ^b   Byrne, James P ^b   Kelly, Jamie J ^b   Bailey, Ian S ^b   Sharland, Donna M ^b   Rees, Charlotte N ^b   Iveson, Timothy J ^b   Underwood, Tim J ^a,b   Bateman, Andrew R ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Esophageal cancer; Gastro esophageal cancer; Neoadjuvant; Regression

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROPYRIMIDINE; OXALIPLATIN; PLATINUM;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY;

ESOPHAGEAL CANCER; GASTRO-ESOPHAGEAL CANCER; NEOADJUVANT; REGRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ENDOSONOGRAPHY; ENGLAND; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84891395942     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i48.9282     Document Type: Article

References (34)

1. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut 2011; 60: 1449-1472 [PMID: 21705456 DOI: 10.1136/gut.2010.228254]
2. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 2009; 22: 1555-1563 [PMID: 19801967 DOI: 10.1038/modpathol.2009.123]
3. Bollschweiler E, Hölscher AH, Metzger R, Besch S, Mönig SP, Baldus SE, Drebber U. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg 2011; 92: 2020-2027 [PMID: 22115212 DOI: 10.1016/ j.athoracsur.2011.06.091]
4. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984 [PMID: 9869669 DOI: 10.1056/ NEJM199812313392704]
5. Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, Yamasaki M, Makari Y, Matsuura N, Mano M, Monden M. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007; 141: 570-580 [PMID: 17462456 DOI: 10.1016/j.surg.2006.11.007]
6. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692 [PMID: 21684205 DOI: 10.1016/S1470-2045(11)70142-5]
7. Ott K, Herrmann K, Krause BJ, Lordick F. The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. Gastrointest Cancer Res 2008; 2: 287-294 [PMID: 19259277]
8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]
9. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-1733 [PMID: 12049861 DOI:10.1016/S0140-6736(02)08651-8]
10. Korst RJ, Kansler AL, Port JL, Lee PC, Kerem Y, Altorki NK. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg 2006; 82: 480-484; discussion 484-485 [PMID: 16863749 DOI: 10.1016/j.athoracsur.2006.03.072]
11. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91: 2165-2174 [PMID: 11391598 DOI: 10.1002/1097-0142(20010601)91]
12. Donington JS, Miller DL, Allen MS, Deschamps C, Nichols FC, Pairolero PC. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg 2003; 24: 631-636; discussion 636-637 [PMID: 14500086 DOI: 10.1016/S1010-7940(03)00397-X]
13. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25: 3719-3725 [PMID: 17704421 DOI: 10.1200/JCO.2006.10.4760]
14. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686 [PMID: 8194005]
15. Hermann RM, Horstmann O, Haller F, Perske C, Christiansen H, Hille A, Schmidberger H, Füzesi L. Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use? Dis Esophagus 2006; 19: 329-334 [PMID: 16984527 DOI: 10.1111/ j.1442-2050.2006.00589.x]
16. Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol 2010; 17: 1159-1167 [PMID: 20140529 DOI:10.1245/s10434-009-0862-1]
17. Verlato G, Zanoni A, Tomezzoli A, Minicozzi A, Giacopuzzi S, Di Cosmo M, Franceschetti I, de Manzoni G. Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci. Br J Surg 2010; 97: 719-725 [PMID: 20306529 DOI:10.1002/bjs.6949]
18. Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006; 106: 2119-2127 [PMID: 16607651 DOI: 10.1002/cncr.21850]
19. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP, Hoelscher AH. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242: 684-692 [PMID: 16244542 DOI: 10.1097/01.sla.0000186170.38348.7b]
20. Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, Parsons SL, Madhusudan S. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 2010; 102: 1600-1607 [PMID: 20461087 DOI: 10.1038/sj.bjc.6605686]
21. Fareed KR, Ilyas M, Kaye PV, Soomro IN, Lobo DN, Parsons SL, Madhusudan S. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Histopathology 2009; 55: 399-406 [PMID: 19817890 DOI: 10.1111/j.1365-2559.2009.03404.x]
22. Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol 2008; 15: 2894-2902 [PMID: 18663531 DOI: 10.1245/s10434-008-0084-y]
23. Akita H, Doki Y, Yano M, Miyata H, Miyashiro I, Ohigashi H, Ishikawa O, Nishiyama A, Imaoka S. Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Dis Esophagus 2009; 22: 291-297 [PMID: 19021686 DOI: 10.1111/j.1442-2050.2008.00879.x]
24. Hardwick RH. A Consensus View and Recommendations on the Development and Practice of Minimally Invasive Oesophagectomy AUGIS/ALSGBI 2008 Available from: URL: http://www.augis.org/news_guidelines/augis_reports.htm
25. UICC. TNM Classification of malignant tumours Seventh edition. America: Wiley-Blackwell, 2009
26. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-196 [PMID: 19638912 DOI: 10.1097/SLA.0b013e3181b13ca2]
27. Bateman AC, Jaynes E, Bateman AR. Rectal cancer staging post neoadjuvant therapy--how should the changes be assessed? Histopathology 2009; 54: 713-721 [PMID: 19438746 DOI: 10.1111/j.1365-2559.2009.03292.x]
28. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004; 101: 1776-1785 [PMID: 15386332 DOI: 10.1002/cncr.20585]
29. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065 [PMID: 11408502]
30. Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg 2008; 206: 239-246 [PMID: 18222375 DOI: 10.1016/j.jamcollsu rg.2007.09.003]
31. Leers JM, Ayazi S, Hagen JA, Terterov S, Klipfel N, Oezcelik A, Abate E, Lipham JC, DeMeester SR, Banki F, DeMeester TR. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status. J Am Coll Surg 2009; 208: 553-556 [PMID: 19476789 DOI: 10.1016/j.jamcollsurg.2009.01.017]
32. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F, Fitzgerald RC. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA 2010; 107: 2177-2182 [PMID: 20080664 DOI: 10.1073/pnas.0909797107]
33. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 4379-4386 [PMID: 17906203 DOI: 10.1200/jco.2007.11.9685]
34. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730 [PMID: 11547741 DOI: 10.1056/NEJMoa010187]